Hemophilia B, a genetic bleeding disorder, is characterized by a deficiency in clotting factor IX. This deficiency impairs the body’s ability to form blood clots properly, leading to prolonged bleeding after injury, surgery, or even spontaneously. The severity of the condition varies, depending on the level of factor IX present in the blood. Individuals with severe Hemophilia B may experience frequent, spontaneous bleeding episodes, while those with milder forms may only bleed excessively after significant trauma.
The alternate name for this condition stems from a significant event in medical history. It is associated with the first documented patient, a young boy named Stephen Christmas, who was diagnosed with the condition in 1952. His case was instrumental in distinguishing this specific type of hemophilia from the more common Hemophilia A (factor VIII deficiency). Identifying and understanding this distinction was crucial for developing specific treatments and therapies tailored to address the factor IX deficiency.
